<?xml version="1.0" encoding="UTF-8"?>
<ref id="B52">
 <label>52.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yang</surname>
    <given-names>C-W</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>Y-Z</given-names>
   </name>
   <name>
    <surname>Hsu</surname>
    <given-names>H-Y</given-names>
   </name>
   <name>
    <surname>Jan</surname>
    <given-names>J-T</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>Y-L</given-names>
   </name>
   <name>
    <surname>Chang</surname>
    <given-names>S-Y</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Inhibition of SARS-CoV-2 by highly potent broad-spectrum anti-coronaviral tylophorine-based derivatives</article-title>. 
  <source>Front Pharmacol.</source> (
  <year>2020</year>) 
  <volume>11</volume>:
  <fpage>606097</fpage>. 
  <pub-id pub-id-type="doi">10.3389/fphar.2020.606097</pub-id>
  <?supplied-pmid 33519469?>
  <pub-id pub-id-type="pmid">33519469</pub-id>
 </mixed-citation>
</ref>
